Global Doxercalciferol Market Size, Share and Trends Analysis Report, By Type (Injection and Capsule), By Application (SHPT in Patients with Chronic Kidney Disease (CKD) on Dialysis and SHPT in Patients with Stage 3 Or Stage 4 Chronic Kidney Disease (CKD)), Forecast (2022-2028)

The global doxercalciferol market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Doxercalciferol is a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism in patients with chronic kidney disease with or without therapy of dialysis and also it treats metabolic bone disease. The major factor expected to drive the market is the increasing incidence of chronic kidney diseases. In 2020, a report published by Kidney Foundation stated that around 4 million people have kidney disease in Canada out of which 46% of new patients are under the age of 65. Additionally, the number of people living with end-stage kidney disease has grown by 35% since 2009. Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxy vitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Further, doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism for Stage 3 or Stage 4 chronic kidney disease patients.

Some major players in the market include Pfizer Inc., Sanofi S.A., Dr Reddy’s Laboratories Ltd., and Lupin Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2019, Lupin Ltd. announced that the company received the approval from US Food and Drug Administration (FDA) to lunch its generic Doxercalciferol injection of 4 mcg/2 mL (2 mcg/mL) used for the treatment of hyperparathyroidism. Further, the company added that the product is a generic version of Sanofi Genzyme’s Hectorol Injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials. Furthermore, in November 2019, Dr. Reddy’s Laboratories Ltd. announced that the company received the approval from US Food and Drug Administration (FDA) to lunch the Doxercalciferol injection of 4 mcg/2 mL (2 mcg/mL) Multiple-Dose Vials, the therapeutic generic equivalent of Hectorol (doxercalciferol) Injection 4 mcg/2 mL (2 mcg/mL) Multiple-Dose Vials.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

• Competitive Landscape– Pfizer Inc., Sanofi S.A., Dr Reddy’s Laboratories Ltd., and Lupin Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Doxercalciferol Market Report by Segment

By Type

• Injection
• Capsule

By Application

• SHPT in patients with chronic kidney disease (CKD) on dialysis
• SHPT in patients with stage 3 or stage 4 chronic kidney disease (CKD)

Global Doxercalciferol Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa